Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia

被引：28

作者：

Francisco, Gerard E. ^{[1
]}

Yablon, Stuart A.

Schiess, Mya C.

Wiggs, Laura

Cavalier, Steven

Grissom, Samuel

机构：

[1] Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA

[2] Inst Rehabil & Res, Brain Injury & Stroke Program, Houston, TX USA

[3] Mississippi Methodist Rehabil Ctr, Brain Injury Program, Jackson, MS USA

[4] Mississippi Methodist Rehabil Ctr, Dept Neurol, Jackson, MS USA

[5] Mem Hermann Hosp, Movement Disorders Clin, UT MOVE, Houston, TX USA

[6] TIRR Challenge Program, Houston, TX USA

[7] Neuromed Ctr, Baton Rouge, LA USA

[8] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA

[9] Kessler Inst Rehabil, Chester, NJ USA

来源：

TOPICS IN STROKE REHABILITATION | 2006年 / 13卷 / 04期

关键词：

baclofen; intrathecal therapy; spasticity; stroke;

D O I：

10.1310/tsr1304-74

中图分类号：

R49 [康复医学];

学科分类号：

100215 ;

摘要：

Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments. Because its use in stroke is not as established as other indications, ITB therapy has not been subjected to rigorous investigation. There is limited evidence to guide clinicians regarding application of this therapy in this patient population. This article aims to review the available scientific literature and the opinion of several experts on the topic. It will also describe the recommendations of these experts with regard to addressing common clinical situations that may influence treatment decisions in the stroke population.

引用

页码：74 / 85

页数：12

共 37 条

[1] Does spasticity contribute to walking dysfunction after stroke? [J].